BriaCell Therapeutics Corp (NASDAQ:BCTX) jumped 11%. Recently the company announced the open enrolment and recruitment in the collaborative Phase I/IIa combination study with Incyte. The study seeks to assess BriaCell’s flagship candidate, Bria-IMT, in combination with Incyte retifinalimab checkpoint inhibitor and epacadostat IDPO1 inhibitor in advanced breast cancer treatment. In addition, the companies are conducting …
Continue reading “BriaCell Therapeutics Corp (NASDAQ:BCTX) Stock Breakout Alert: How to Trade Now?”